Background/Aims: The aim of this study was to explore the relationship between hypertriglyceridemic waist (HW) phenotype and early diabetic nephropathy in type 2 diabetes. Methods: A cross-sectional study was conducted on 538 type 2 diabetes patients in Qinhuangdao. The HW phenotype was defined as serum triglyceride concentrations ≥1.7 mmol/L and waist circumference ≥90 cm (males) and ≥85 cm (females). Results: The prevalence of the HW phenotype was 34.9%. The prevalence of early diabetic nephropathy was 10.6% in type 2 diabetes patients with normal waist circumference and triglycerides and 24.5% in type 2 diabetes patients with HW phenotype. After adjustment for sex, age, body mass index, hypertension, history of diabetes, and glycosylated hemoglobin A1c, the prevalence of early diabetic nephropathy among type 2 diabetes patients with the HW phenotype was 2.81 (95% confidence interval 1.36-5.80, p = 0.005) times higher than that among type 2 diabetes patients with normal waist circumference and triglycerides. Conclusion: There was a significant correlation between HW phenotype and early diabetic nephropathy in type 2 diabetes.

Keywords:
Hypertriglyceridemic waist phenotype, Early diabetic nephropathy, Type 2 diabetes
1.
Lemieux I, et al: Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 2000;102:179-184.
2.
Liu MB, Wang W, Zhou MG: Trend analysis on the mortality of cardiovascular diseases from 2004 to 2010 in China (in Chinese). Zhonghua Liu Xing Bing Xue Za Zhi 2013;34:985-988.
3.
Zhang X, et al: Visceral adiposity and risk of coronary heart disease in relatively lean Chinese adults. Int J Cardiol 2013;168:2141-2145.
4.
Chen K, et al: Sex disparity in the association between hypertriglyceridemic waist phenotype and arterial stiffness in Chinese healthy subjects. Postgrad Med 2016;128:783-789.
5.
Xu Y, et al: Prevalence and control of diabetes in Chinese adults. JAMA 2013;310:948-959.
6.
Du T, et al: Visceral adiposity index, hypertriglyceridemic waist and risk of diabetes: the China Health and Nutrition Survey 2009. Int J Obes (Lond) 2014;38:840-847.
7.
Ren Y, et al: Association of the hypertriglyceridemic waist phenotype and type 2 diabetes mellitus among adults in China. J Diabetes Investig 2016;7:689-694.
8.
Zhang M, et al: Hypertriglyceridemic-waist phenotype predicts diabetes: a cohort study in Chinese urban adults. BMC Public Health 2012;12:1081.
9.
Han KJ, et al: Increased risk of diabetes development in subjects with the hypertriglyceridemic waist phenotype: a 4-year longitudinal study. Endocrinol Metab (Seoul) 2014;29:514-521.
10.
He S, et al: Hypertriglyceridemic waist might be an alternative to metabolic syndrome for predicting future diabetes mellitus. PLoS One 2013;8:e73292.
11.
de Graaf FR, et al: Usefulness of hypertriglyceridemic waist phenotype in type 2 diabetes mellitus to predict the presence of coronary artery disease as assessed by computed tomographic coronary angiography. Am J Cardiol 2010;106:1747-1753.
12.
St-Pierre J, et al: Relation of the “hypertriglyceridemic waist” phenotype to earlier manifestations of coronary artery disease in patients with glucose intolerance and type 2 diabetes mellitus. Am J Cardiol 2007;99:369-373.
13.
Yokoyama H, et al: Subclinical atherosclerosis is increased in type 2 diabetic patients with microalbuminuria evaluated by intima-media thickness and pulse wave velocity. Kidney Int 2004;66:448-454.
14.
American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2014;37(suppl 1):S81-S90.
15.
Chinese Diabetes Society: Chinese guideline for type 2 diabetes. Chin J Endocrinol Metab 2014;30:893-942.
16.
Mogensen CE, Christensen CK, Vittinghus E: The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes 1983;32(suppl 2):64-78.
17.
Bao Y, et al: Optimal waist circumference cutoffs for abdominal obesity in Chinese. Atherosclerosis 2008;201:378-384.
18.
Zeng J, et al: The association of hypertriglyceridemic waist phenotype with chronic kidney disease and its sex difference: a cross-sectional study in an urban Chinese elderly population. Int J Environ Res Public Health 2016;13:1233.
19.
Huang J, et al: Visceral adiposity index, hypertriglyceridemic waist phenotype and chronic kidney disease in a southern Chinese population: a cross-sectional study. Int Urol Nephrol 2015;47:1387-1396.
20.
Li Y, et al: Hypertriglyceridemic waist phenotype and chronic kidney disease in a Chinese population aged 40 years and older. PLoS One 2014;9:e92322.
21.
Zhe X, et al: Hypertriglyceridemic waist is associated with increased carotid atherosclerosis in chronic kidney disease patients. Nephron Clin Pract 2012;122:146-152.
22.
Borruel S, et al: Surrogate markers of visceral adiposity in young adults: waist circumference and body mass index are more accurate than waist hip ratio, model of adipose distribution and visceral adiposity index. PLoS One 2014;9:e114112.
23.
Hanai K, et al: Involvement of visceral fat in the pathogenesis of albuminuria in patients with type 2 diabetes with early stage of nephropathy. Clin Exp Nephrol 2010;14:132-136.
24.
Foster MC, et al: Association of subcutaneous and visceral adiposity with albuminuria: the Framingham Heart Study. Obesity (Silver Spring) 2011;19:1284-1289.
25.
Cunha de Oliveira C, et al: Hypertriglyceridemic waist phenotype: association with metabolic disorders and visceral fat in adults. Nutr Hosp 2014;30:25-31.
26.
Sam S, et al: Hypertriglyceridemic waist phenotype predicts increased visceral fat in subjects with type 2 diabetes. Diabetes Care 2009;32:1916-1920.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.